Cas:56843-28-8 2,4-dichlorobenzaldehyde oxime manufacturer & supplier

Chemical Name:2,4-dichlorobenzaldehyde oxime

CAS.NO:56843-28-8

Synonyms:2,4-dichloro-benzaldehydoxime;2,4-dicholorobenzaldehydeoxime;2,4-dichlorobenzadehyde oxime;2,4-dichloro-benzaldehyde-oxime;HONCHC6H3Cl2-2,4;2,4-Dichlor-benzaldehyd-oxim

Molecular Formula:C₇H₅Cl₂NO

Molecular Weight:190.02700

HS Code:

Physical and Chemical Properties:

Melting point:134ºC

Boiling point:271.3ºC at 760mmHg

Density:1.38g/cm3

Index of Refraction:1.575

PSA:32.59000

Exact Mass:188.97500

LogP:2.80150

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2,4-dichloro-benzaldehydoxime chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4-Dichlor-benzaldehyd-oxim physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4-dichloro-benzaldehyde-oxime Use and application,HONCHC6H3Cl2-2,4 technical grade,usp/ep/jp grade.

Related News: Further research on Oligomannate��s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement. 2,4-dichlorobenzaldehyde oxime manufacturer The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs. 2,4-dichlorobenzaldehyde oxime supplier Bulk bulk medicines: overcapacity, low prices, future capacity and output will be reduced, and it is possible to transfer foreign production. 2,4-dichlorobenzaldehyde oxime vendor In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn. 2,4-dichlorobenzaldehyde oxime factory In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.